With a 23 percent increase in product sales, Genentech Inc. chalked up earnings in the second quarter of 31 cents per share, a 35 percent jump in EPS, figured on a non-GAAP (generally accepted accounting principles, formerly known as pro forma) basis. (BioWorld Today)